Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trialRandomized Controlled Trial Published on 2022-10-012022-10-04 Journal: Journal of Clinical Virology [Category] COVID19(2023년), SARS, 임상, [키워드] absence Administered analysed Anti-spike clinical clinical symptom clinical trial co-morbidity Community Course COVID-19 COVID-19 pandemic double blind Effect Efficacy and safety eligibility criteria evaluate Evaluating healthcare Immunoglobulin Infection nasal offer participant Placebo placebo-controlled placebo-controlled trial positive primary end point Prophylactic Prophylaxis random randomised Randomised trial Randomized reduced Result Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2. significantly subject tested the primary endpoint the spike protein Treatment vaccination [DOI] 10.1016/j.jcv.2022.105248 PMC 바로가기 [Article Type] Randomized Controlled Trial
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] antibodies benefit clinical conducted convalescent plasma Convalescent plasma therapy Course COVID-19 death determine died disease severity double blind duration of symptoms Effectiveness Endpoint enrolment Follow-up hazard ratio high-risk patient highest Hospital admission Hospitalized ICU admission IMPROVE in viral median age multicentre objective Odds ratio Older Outpatient outpatients Patient PCR primary endpoint randomization randomized placebo-controlled trial randomized trial recruitment Result risk factor RNA secondary severe COVID-19 Symptom symptom duration symptom onset symptomatic Symptoms the disease therapy for COVID-19 vaccination Viral RNA [DOI] 10.1016/j.cmi.2022.08.005 [Article Type] Research article
Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: A randomized, double-blinded, placebo controlled clinical trialRandomized Controlled Trial Published on 2022-08-012022-10-05 Journal: Complementary therapies in medicine [Category] SARS, 임상, [키워드] acute COVID-19 acute infection Analysis aromatherapy assigned baseline BMI boost conducted Controlled clinical trial COVID-19 Diagnosis double blind double-blinded effect size employment Essential evaluate Evidence fatigue female FIVE group healthy IMPROVE individual Infection Inhaled Insomnia Intervention inventory lack Mental Oil olfactory function outcome Placebo placebo controlled trial proportion provide Quality of life Randomized recovering from COVID-19 secondary serious complication significantly significantly lower survivor Symptom the United State USA Utah were measured women [DOI] 10.1016/j.ctim.2022.102823 PMC 바로가기 [Article Type] Randomized Controlled Trial
Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled TrialRandomized Controlled Trial Published on 2022-07-262022-10-05 Journal: Nutrients [Category] COVID19(2023년), SARS, 임상, [키워드] addition administration calcifediol cholecalciferol circulating Clinical improvement Clinical outcome clinical recovery COVID COVID-19 COVID-19 patient COVID-19 severity Day deficiency demonstrated double blind Effect enrolled Hospital stay Hospitalization Hospitalized Mortality Patient patients per day pilot study Placebo Randomized reduced SARS-CoV-2 SARS-CoV-2 positivity significantly significantly lower still hospitalized subject supplemental oxygen the patient the placebo group the WHO therapy treated Vitamin D Vitamin D status Vitamin D supplementation vitamin D. with COVID-19 [DOI] 10.3390/nu14153048 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effect of Omega-3 fatty acid supplementation on sexual function of pregnant women: a double blind randomized controlled trial Research Published on 2022-07-192022-10-05 Journal: International Journal of Impotence Research [Category] 임상, [키워드] Anxiety approved baseline clinical control group control groups Controlled clinical trial Data collection double blind double-blind Effect Effectiveness Energy intake ethics committee evaluate the effect fatty female Follow-up gestation health center IMPROVE Intervention intervention group Medical Science omega-3 omega-3 fatty acid omega-3 supplement performed Placebo Polyunsaturated Pregnancy pregnant pregnant women prenatal care questionnaire Randomized Randomized controlled trial recall receive Registered registry significantly higher significantly lower statistically significant statistically significant difference the mean total score university Van [DOI] 10.1038/s41443-022-00598-w [Article Type] Research
Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trialRandomized Controlled Trial Published on 2022-07-122022-10-04 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 임상, [키워드] assessment baseline Brain brain tissue caused changes in clinical cognitive Cognitive function demonstrated domain double blind emotional evaluated executive fatigue function Hyperbaric oxygen therapy hypercoagulability IMPROVE induce Infection Interaction Invasion mechanism MRI Neuroinflammation outcome Oxygen therapy Pain pathology Patient performed physical post-COVID-19 patient precentral Psychiatric radiate Randomized Randomized controlled trial receive Region SARS-COV-2 infection Significant supplementary motor area Symptom therapy Treatment Trial virus [DOI] 10.1038/s41598-022-15565-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Complement activation in COVID-19 and targeted therapeutic options: A scoping reviewReview article Published on 2022-07-012022-10-05 Journal: Blood reviews [Category] COVID19(2023년), SARS, 바이오마커, 임상, [키워드] Activation approach article C5a complement Complement activation Complement cascade complement inhibition Complement pathway Coronavirus disease 2019 correlation COVID-19 disease severity double blind Evidence histopathological Increasing Mortality observational study Pathogenesis RCT review SARS-CoV-2 screened therapeutic [DOI] 10.1016/j.blre.2022.100995 [Article Type] Review article
Novel TB smear microscopy automation system in detecting acid-fast bacilli for tuberculosis – A multi-center double blind studyRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Tuberculosis (Edinburgh, Scotland) [Category] 임상, [키워드] Accuracy Action artificial artificial intelligence Automated microscope complement connection COVID-19 pandemic Culture diagnosed Diagnosis discrepancy double blind double-blind trial Efficiency enrolled evaluate gold standard Laboratory manual Medical resources Microscopy mitigate molecular Negative predictive value novel Prevalence pulmonary tuberculosis recent reduce Result sensitivity Sensitivity and specificity smear microscopy TB Smears. Total Tuberculosis [DOI] 10.1016/j.tube.2022.102212 PMC 바로가기 [Article Type] Randomized Controlled Trial
A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 diseaseResearch article Published on 2022-04-012022-10-05 Journal: New Microbes and New Infections [Category] 임상, 치료제, [키워드] accelerated Administered administration adverse event Analysis ARMS bpm clinical recovery clinical trial cough COVID-19 COVID-19 disease COVID-19 patients COVID-19 symptom COVID-19 symptoms Day defined disease dose double blind Dyspnea Efficacy evaluated exhibited facilitate FDA-Approved Regimen for Malaria Pophylaxis Fever Hospitalization individual ITT population Mild Moderate COVID-19 occurred Outpatient outpatients Patient per day Placebo placebo-controlled PP population primary endpoint proportion Randomized recorded respiratory rate response Shortness of breath tafenoquine the primary endpoint Therapeutic benefit time Trial [DOI] 10.1016/j.nmni.2022.100986 [Article Type] Research article
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in LagosRandomized Controlled Trial Published on 2022-01-052022-10-05 Journal: QJM: An International Journal of Medicine [Category] SARS, 임상, [키워드] 95%CI ANOVA clinical benefit Clinical management conducted Control controls correlated COVID COVID 19 COVID19 Day dose dose response double blind double-blind Efficacy Efficacy and safety group high risk inhibit Lago Lopinavir/ritonavir Mild moderate negativity parallel group Patient Placebo Platelet positive patients Prophylaxis question Randomized reduced remained repeated measure reported SAE shown significantly the SARS-CoV-2 translational Treatment treatment groups viral replication [DOI] 10.1093/qjmed/hcab035 PMC 바로가기 [Article Type] Randomized Controlled Trial